Trevi Therapeutics (TRVI) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

1d ago, source:

Trevi Therapeutics (TRVI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement ...

Trevi Therapeutics Inc (TRVI)

10d ago, source: Investing

Trevi Therapeutics, Inc. (NASDAQ:TRVI) provided an update on its clinical trials and financial results during its fourth quarter and year-end 2023 earnings conference ...

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2023 Earnings Call Transcript

29d ago, source: InvestingChannel on MSN

Trevi Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.08, expectations were $-0.1. TRVI isn't one of the ...

Trevi Therapeutics Inc (TRVI) Announces Year-End Financials and Progress in Clinical Trials

1mon ago, source: Yahoo Finance

Warning! GuruFocus has detected 3 Warning Signs with TRVI. On March 20, 2024, Trevi Therapeutics Inc (NASDAQ:TRVI) released its 8-K filing, disclosing its fourth quarter and full-year financial ...

Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates

29d ago, source: WCBD

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic ...

Trevi Therapeutics, Inc. (TRVI) Q4 2023 Earnings Call Transcript

29d ago, source: Seeking Alpha

Good afternoon, and welcome to the Trevi Therapeutics Fourth Quarter and Year-End 2023 Earnings Conference Call. At this time, all participants will be in listen-only mode. [Operator Instructions ...

Trevi Therapeutics Inc TRVI

15d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates

29d ago, source: Finanznachrichten

March 20, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio (oral nalbuphine ER) for the ...